The estimated Net Worth of Teresa Mc Carthy is at least $1.71 Миллион dollars as of 17 June 2024. Ms Carthy owns over 9,864 units of Avidity Biosciences stock worth over $1,304,212 and over the last 3 years she sold RNA stock worth over $406,897.
Ms has made over 2 trades of the Avidity Biosciences stock since 2024, according to the Form 4 filled with the SEC. Most recently she sold 9,864 units of RNA stock worth $385,978 on 17 June 2024.
The largest trade she's ever made was selling 9,864 units of Avidity Biosciences stock on 17 June 2024 worth over $385,978. On average, Ms trades about 2,386 units every 30 days since 2022. As of 17 June 2024 she still owns at least 32,171 units of Avidity Biosciences stock.
You can see the complete history of Ms Carthy stock trades at the bottom of the page.
Teresa McCarthy is the Chief HR Officer at Avidity Biosciences.
Teresa's mailing address filed with the SEC is C/O AVIDITY BIOSCIENCES, INC., 10578 SCIENCE CENTER DRIVE, SUITE 125, SAN DIEGO, CA, 92121.
Over the last 4 years, insiders at Avidity Biosciences have traded over $8,545,325 worth of Avidity Biosciences stock and bought 2,050,000 units worth $36,900,000 . The most active insiders traders include Investments, Lpwong Roderic..., Lilly & Co Eli и Asset Management, Lp Chen B.... On average, Avidity Biosciences executives and independent directors trade stock every 34 days with the average trade being worth of $3,142,336. The most recent stock trade was executed by Arthur A Levin on 19 August 2024, trading 5,000 units of RNA stock currently worth $6,200.
Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease; AOC 1044 for the treatment of Duchenne Muscular Dystrophy; and AOC 1020 designed to treat facioscapulohumeral muscular dystrophy which are in preclinical stage. It also offers Lumizyme therapy for Pompe diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.
Avidity Biosciences executives and other stock owners filed with the SEC include: